Li Yiqing, Tang Ting, Xiao Jie, Wang Jieyu, Li Boqi, Ma Liping, Xie Shuangfeng, Nie Danian
Department of Hematology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong 510120, People's Republic of China.
Open Med (Wars). 2021 Apr 8;16(1):610-617. doi: 10.1515/med-2020-0196. eCollection 2021.
Nocardiosis is a rare, life-threatening, opportunistic, and suppurative infection. Its clinical manifestation lacks specificity, which makes early diagnosis difficult. A retrospective analysis of the clinical records of 11 patients with nocardiosis admitted to our hospital from January 2013 to November 2018 was conducted. All patients had at least one underlying disorder, such as an autoimmune disease (6/11), a blood malignancy (2/11), avascular necrosis of the femoral head (1/11), bronchiectasis (1/11), or pneumonia (1/11). The first-line treatment was trimethoprim-sulfamethoxazole (TMP-SMX); one or two additional antibiotics were given according to the drug-sensitive test. The median time from onset to treatment was 3 weeks (ranging from 1 to 9 weeks). The median duration of treatment after diagnosis was 20.5 weeks (ranging from 7 to 47 weeks). Eight patients were discharged and survived, and three patients died. This indicates that early use of TMP-SMX combined with sensitive antibiotics could improve the condition of patients and improve the cure rate (8/11). Clinically, it is necessary to consider the possibility of nocardiosis in patients with long-term use of immunosuppressants and poor response to treatment of common bacterial infections. Early diagnosis, timely treatment, and combination drug therapy are keys to improving the outcomes of patients with nocardiosis.
诺卡菌病是一种罕见的、危及生命的、机会性化脓性感染。其临床表现缺乏特异性,导致早期诊断困难。对2013年1月至2018年11月我院收治的11例诺卡菌病患者的临床记录进行回顾性分析。所有患者至少有一种基础疾病,如自身免疫性疾病(6/11)、血液系统恶性肿瘤(2/11)、股骨头缺血性坏死(1/11)、支气管扩张(1/11)或肺炎(1/11)。一线治疗为复方磺胺甲恶唑(TMP-SMX);根据药敏试验加用一种或两种其他抗生素。从发病到治疗的中位时间为3周(1至9周)。诊断后治疗的中位持续时间为20.5周(7至47周)。8例患者出院存活,3例患者死亡。这表明早期使用TMP-SMX联合敏感抗生素可改善患者病情,提高治愈率(8/11)。临床上,对于长期使用免疫抑制剂且对常见细菌感染治疗反应不佳的患者,有必要考虑诺卡菌病的可能性。早期诊断、及时治疗和联合药物治疗是改善诺卡菌病患者预后的关键。